The crystalline 2,3,4-trifluoronitrobenzene powder is conditioned at 25 ± 2 °C and 30 ± 5 % RH before direct-compression trials because adsorbed water above 0.5 % w/w increases cohesive bridging in the feed frame and elevates ejection force on a 16-station rotary tablet press fitted with 8.0 mm round D-tooling. A direct-compression blend targeting 5.0 % w/w drug loading is prepared by charging spray-dried lactose monohydrate and microcrystalline cellulose in a 1:1 mass ratio to a 300 L bin blender, followed by croscarmellose sodium at 2.0 % w/w and colloidal silicon dioxide at 0.3 % w/w. The primary blending interval is 15 min at 25 rpm; magnesium stearate at 0.5 % w/w is then introduced and blended for 3 min. Because published compressibility data for this specific trifluorinated nitroaromatic entity are limited, a compaction simulator is used at 5 kN, 8 kN, and 12 kN to define the acceptable hardness range before scale-up. The finished tablets are compressed to a hardness of 40–80 N and a friability of NMT 1.0 % per USP <1216>, with weight variation and content uniformity evaluated according to USP <905>. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl with 0.5 % w/w sodium dodecyl sulfate when the aqueous solubility is below 0.1 mg/mL; sink conditions must be confirmed before setting the Q value. The film-coating step is performed in a perforated pan with a 15–18 g/min spray rate and 40–45 °C inlet air to a 2.5 % w/w weight gain, and if ICH Q1B visible-light stress produces a total impurity increase above 0.05 % area, the tablets are transferred to amber PVC/PVDC blister cavities within 4 h.

For materials exhibiting a Carr index above 25 % or an angle of repose above 40° under USP <1174>, direct compression may be replaced by roller compaction. The direct-compression platform is nevertheless suitable when the incoming lot meets a bulk density of 0.38–0.50 g/mL and tapped density of 0.52–0.68 g/mL according to USP <616>. Blend uniformity samples are withdrawn from 10 locations and require an assay RSD of NMT 5.0 % before compression. In-process metal detection on the tablet press discharge chute is set to reject tablets containing ferrous particles above 0.5 mm, while non-ferrous detection follows 21 CFR 211.84 component inspection requirements for incoming excipients. The final dosage form is a round biconvex film-coated tablet intended for oral administration, with release testing including assay, related substances, dissolution, water content, and microbial limits according to USP <61> and USP <62>.

Roller Compaction Ribbon Density as a Fracture Predictor

Roller compaction becomes necessary when a direct-compression blend containing 2,3,4-trifluoronitrobenzene exhibits a Hausner ratio above 1.34 or when the API fraction exceeds 10 % w/w and causes flow stoppage in the press feed frame. The pre-compacted mixture is passed through a roller compactor with 25 mm knurled rolls set to a gap of 2.0 mm and a specific hydraulic force of 8–14 kN/cm. Ribbon density is monitored by envelope-density pycnometry at 0.85–1.05 g/cm³; values below 0.80 g/cm³ generate fines that increase recompression capping, while values above 1.15 g/cm³ reduce granule compressibility and prolong tablet disintegration. Milling through a FitzMill equipped with a 0.8 mm screen produces granules with a retained fraction between 250 µm and 850 µm, and the accept range is set at ≥ 65 % w/w of the milled output. Crospovidone is split at 1.5 % w/w intragranular and 1.5 % w/w extragranular to preserve disintegration performance after the work-hardening effect of roll compaction.

Final compression of the dry granulate is carried out at 12–20 kN on a rotary press with 9.0 mm round B-tooling, and the resulting tablets are evaluated for tensile strength, friability, and content uniformity. Process limits require a compression force RSD of NMT 4.0 % across 30 min of continuous operation, and tablet weight variation must remain within ± 5 % under 21 CFR 211.165 release testing. Residual moisture after dry granulation is controlled at NMT 0.8 % w/w by USP <731> because moisture above this threshold increases ribbon adhesion and can promote nitroarene-related surface discoloration. The dry-granulated tablets may be packaged in amber glass or high-barrier blister stock if photo-instability is confirmed by ICH Q1B testing. The finished product is an immediate-release oral tablet manufactured without solvent addition, with batch records documenting ribbon density, mill screen integrity, and metal contamination checks using a 0.75 mm screen on the granulation discharge line.

Automatic capsule filling of a low-bulk-density trifluorinated nitroaromatic powder entering an ISO 14644-1 Class 8 zone requires a tamping-pin or vacuum-drum machine to handle fill weight control below 220 mg. A powder-in-capsule blend containing 10 % w/w 2,3,4-trifluoronitrobenzene pharma grade, 65 % w/w mannitol, 24.5 % w/w pregelatinized starch, and 0.5 % w/w sodium stearyl fumarate is prepared in a 600 L tumble blender at 18 rpm for 20 min. Fill weight is targeted at 200 mg per size-3 hydroxypropyl methylcellulose capsule with an individual fill-weight acceptance range of 190–210 mg. The tamping-pin machine is set with a pin compression depth of 14 mm and pin board speed of 60 strokes/min; fill weight variability must remain below 2.0 % RSD over 30 min of sampled operation. In-process checks follow USP <905>, and blend assay samples require 90–110 % of label claim with an RSD of NMT 5.0 % before the fill campaign is released.

Because the aromatic nitro group can be sensitive to light and reductive impurities, the filled capsules are protected from direct UV illumination during transfer and are stored in sealed HDPE drums containing desiccant when the storage-area relative humidity exceeds 60 % RH. Dissolution testing of the finished capsules follows USP <711> Apparatus 1 at 100 rpm in 900 mL of pH 4.5 acetate buffer; if the compound demonstrates a dissolution plateau below 85 % in 60 min, the formulation is reformulated with a wetting agent such as sodium lauryl sulfate at 0.1–0.3 % w/w. Capsule shell moisture is controlled at 12.0–16.0 % w/w to prevent brittle fracture during the filling machine’s opening-and-closing cycle. The final dosage form is an immediate-release capsule intended for oral administration, with release testing for content uniformity, dissolution, related substances, water content, and microbial limits according to USP <61> and USP <62>.

When Isopropyl Alcohol Replaces Water in High-Shear Granulation of a Trifluorinated Nitroarene

High-shear wet granulation may be required to improve density and flow when roller compaction produces ribbon capping or the API particle size distribution has a D50 below 25 µm. For a nitroarene with low aqueous solubility and possible photochemical instability, isopropyl alcohol is selected as the granulation solvent instead of purified water. Povidone K30 is dissolved in isopropyl alcohol to a concentration of 5 % w/w, and the binder solution is added at 18–22 % w/w relative to the dry powder mass. Granulation is performed in a high-shear mixer with a main impeller speed of 300 rpm and a chopper speed of 1500 rpm; wet massing time is held at 4–6 min because extended massing increases agglomerate size beyond 1000 µm and slows drying. The wet granules are transferred to a fluid-bed dryer with an inlet air temperature of 50 °C and dried until the granule loss-on-drying is NMT 1.0 % w/w by USP <731>. After drying, the granulation is milled through a 1.0 mm screen, and the fraction between 150 µm and 850 µm is collected for tableting.

The dried granulate is lubricated with magnesium stearate at 0.5 % w/w and compressed into 10.0 mm round tablets at a hardness of 60–90 N. Residual isopropyl alcohol must be below 5000 ppm to comply with ICH Q3C Option 1, and the batch record includes a drying-curve sample every 10 min until the limit is met. If the nitroarene is susceptible to reduction by trace metal impurities, the granulation fluid is passed through a 0.22 µm filter before addition, and the product-contact surfaces of the high-shear mixer must be verified as 316L stainless steel with no copper or iron exposure above 10 µg/g in the final granulate. The finished oral tablet is tested for dissolution in 0.01 N HCl at 50 rpm and for related substances following forced degradation under acidic, oxidative, thermal, and photolytic conditions. This non-aqueous granulation route minimizes residual-water-mediated hydrolysis while meeting USP <905> uniformity and USP <1216> friability requirements.

Why Does Pre-Filtration Bioburden Monitoring Limit Terminal Load in Aseptic Injectable Processing?

An injectable solution of 2,3,4-trifluoronitrobenzene pharma grade is prepared under ISO 14644-1 Class 5 conditions when the molecule demonstrates adequate solubility and chemical stability in an aqueous vehicle, or when a co-solvent system is required to reach a target concentration of 1 mg/mL or higher. Aseptic processing is preferred over terminal steam sterilization when forced-degradation studies show that exposure to 121 °C for 15 min increases total related substances by more than 0.05 % area. The compounding vessel is inerted with filtered nitrogen, and the solution pH is adjusted to 4.0–5.0 with 0.1 N HCl or 0.1 N NaOH. If the aqueous solubility is below 0.5 mg/mL, a co-solvent containing 10 % v/v polyethylene glycol 400 in Water for Injection is evaluated, and the solution osmolality is adjusted to 280–320 mOsmol/kg with sodium chloride. The bulk solution is filtered through a 0.22 µm PVDF membrane at a differential pressure not exceeding 1.7 bar, followed by a second sterile-grade filter in series at the point of fill.

Pre-filtration bioburden is monitored from the start of compounding through the end of filtration; the action limit is 10 CFU/100 mL, and the alert limit is 5 CFU/100 mL, using membrane filtration according to USP <61> with sample volumes of 100 mL. The purpose of this monitoring is to prevent endotoxin buildup and filter fouling, because a nitroaromatic compound with limited water solubility can precipitate on membrane surfaces when the filter load increases. Sterile filtration is followed by filling into 3 mL Type I borosilicate glass vials at a target fill volume of 2.0 mL. The filled vials are sampled for particulate matter according to USP <788> Method 1; limits are NMT 6000 particles at ≥ 10 µm and NMT 600 particles at ≥ 25 µm per container. Bacterial endotoxin testing follows USP <85>, and the acceptance limit is calculated from the maximum bolus dose, commonly 0.5 EU/mg or tighter when the dose exceeds 5 mg/kg body weight. Sterility testing is completed per USP <71> with 14-day incubation.

The solution should not be compounded with primary amine buffers such as tromethamine unless forced-degradation studies demonstrate no aniline derivative formation, because electron-deficient nitroarenes can undergo nucleophilic substitution under alkaline pH and elevated temperature. Thiol-based antioxidants should be avoided without verification because nitro group reduction may generate reactive intermediates. The final injectable product is an aqueous solution for intravenous or intramuscular administration, packaged in amber glass vials with flip-off seals. In-process line clearances, filter integrity testing by bubble point or diffusion flow, and environmental monitoring data are reviewed under 21 CFR 211.165 and 21 CFR 211.167 before batch release.

Spray-Dried Dispersion and Fluid-Bed Granule Layering for Stick-Pack Oral Delivery

For oral granules intended as a stick-pack dosage form, a spray-dried intermediate may be generated when the crystalline nitroarene exhibits poor dissolution and requires amorphous stabilization. Hypromellose acetate succinate LF grade is dissolved in an 80:20 acetone-water system, and 2,3,4-trifluoronitrobenzene is added at 25 % w/w relative to polymer. The feed solution is spray-dried on a laboratory-scale spray dryer with a 90 °C inlet temperature, 45 °C outlet temperature, and feed rate of 0.5 kg/h. The resulting spray-dried dispersion is then layered onto sugar spheres of 710–850 µm in a fluid-bed coater with a hydroxypropyl cellulose binder solution at 3 % w/w solids in purified water. Spray rate is maintained at 5–8 g/min with a product temperature of 35–40 °C, and the process is stopped when the drug-layer weight gain reaches 120 % w/w of the initial core weight.

Residual acetone is controlled below 5000 ppm according to ICH Q3C, and the final granule moisture is held at NMT 2.0 % w/w by USP <921> Karl Fischer titration. The granules are passed through a 1.4 mm sieve and the fraction 850–1400 µm is filled into stick-packs at a fill weight of 1.0 g. In-process fill weight variation must remain within ± 5 %, and the final package is sealed with a polyethylene terephthalate/aluminum/polyethylene laminate to limit oxygen and moisture ingress. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 500 mL of pH 4.5 acetate buffer, and the product is also tested for content uniformity according to USP <905>. The finished stick-pack granule is intended for oral administration after dispersion in a small volume of water, and the batch record includes the spray-dried dispersion’s glass transition temperature before and after drying; a Tg below 45 °C is not accepted because product handling above that temperature may cause sticking in the fluid-bed filter bags.

Lyophilization is selected when aqueous solution stability at 5 ± 3 °C exceeds 48 h but long-term storage under ICH Q1A accelerated conditions fails the 0.05 % total degradation threshold. A lyophilized formulation containing 4 % w/v mannitol as a bulking agent is prepared in Water for Injection, and the solution is filled at 2.0 mL into 5 mL Type I glass vials. The filled vials are loaded into a Lyostar 3 freeze dryer with a shelf-freezing ramp from 5 °C to -45 °C at 0.5 °C/min and held for 2 h. Primary drying is conducted at -20 °C shelf temperature and 100 mTorr chamber pressure for 36 h; secondary drying is then carried out at 25 °C and 50 mTorr for 6 h. If the collapse temperature is below -18 °C by freeze-drying microscopy, the primary drying shelf must be held at least 2 °C below collapse temperature to prevent cake shrinkage.

After stoppering under nitrogen, the lyophilized cake is tested for residual moisture at NMT 1.0 % w/w by USP <921>, and reconstitution time at 25 °C must not exceed 2 min when 2.0 mL of Water for Injection is added. Particulate matter after reconstitution is controlled under USP <788>, and the vial headspace oxygen is maintained below 2.0 % v/v using an oxygen-sensitive headspace analyzer. The freeze-dried product is intended for injectable administration after reconstitution, and the batch record includes cake appearance score, moisture content, sterility under USP <71>, and bacterial endotoxin under USP <85>. An incompatible combination is the use of reducing sugar bulking agents such as dextrose without forced-degradation support, because the nitroaromatic moiety may be chemically reduced under thermal stress in the lyophilization chamber if amorphous water remains in the cake. Published data for this specific molecular entity in long-term lyophilized stability are limited, so a bracketed stability study at 25 °C/60 % RH, 30 °C/65 % RH, and 40 °C/75 % RH is required before commercial batch release.